Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00278941 · ClinicalTrials.gov registry record · Phase 3
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
NCT00278941: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00278941 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 3,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (289% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00278941, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
The purpose of this study is to determine safety \& efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo \& to evaluate quality of sleep, overall quality of life, and effect, if any, on anxiety and satisfaction PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Interventions
- DRUG Quetiapine Fumarate Sustained Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
What the finished NCT00278941 record still lists
NCT00278941 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (289% higher).
The record links to 0 conditions, and to 1 intervention - of which Quetiapine Fumarate Sustained Release is the first listed.
NCT00278941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00278941 about?
NCT00278941 is a clinical study titled "Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder". The purpose of this study is to determine safety \& efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo \& to evaluate quality of sleep, overall quality of life, and effect, if any, on anxiety and satisfaction PLEASE NOTE: Seroquel SR and Seroquel XR refer to t...
What is the current status of trial NCT00278941?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants. The study started on 2005-12. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00278941?
The interventions under investigation include: Quetiapine Fumarate Sustained Release (DRUG).
Who is sponsoring clinical trial NCT00278941?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00278941's enrollment target sits among peer trials
3,000 79th of 2000 higher than 1,921 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia